There is an emerging consensus that the toxic effects of PARP inhibition in tumour cells result from inhibitor-bound PARP being retained, or trapped, on DNA lesions, thereby blocking replication and repair, but the underlying molecular mechanisms responsible for such trapping have so far been elusive (9). The gene discussed is PARP1; the disease is neoplasm.